A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).
Status:
Completed
Trial end date:
2019-10-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of
GDC-0853 compared with placebo in participants with Refractory Chronic Spontaneous Urticaria
(CSU) already treated with anti-histamines. Participants have the option to enter the
Open-Label Extension (OLE) study after completing the 8-week treatment period.